Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

被引：4

作者：

Salwender, Hans ^{[1
]}

Elmaagacli, Ahmet ^{[2
]}

Merz, Maximilian ^{[3
]}

Miah, Kaya ^{[4
]}

Benner, Axel ^{[4
]}

Haenel, Mathias ^{[5
]}

Jehn, Christian ^{[2
]}

Mai, Elias K. ^{[6
]}

Bertsch, Uta ^{[6
,7
]}

Blau, Igor W. ^{[8
]}

Scheid, Christof ^{[9
]}

Hose, Dirk ^{[10
]}

Seckinger, Anja ^{[10
]}

Jauch, Anna ^{[11
]}

Raab, Marc S. ^{[6
]}

Luntz, Steffen P. ^{[12
]}

Besemer, Britta ^{[13
]}

Munder, Markus ^{[14
]}

Brossart, Peter ^{[15
]}

Fuhrmann, Stephan ^{[16
]}

Lindemann, Hans-Walter ^{[17
]}

Weisel, Katja ^{[18
]}

Duerig, Jan ^{[19
]}

Goldschmidt, Hartmut ^{[6
,7
]}

机构：

[1] AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[2] Allgemein Krankenhaus St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[3] Univ Hosp Leipzig, Dept Hematol Celltherapy & Hemostaseol, Leipzig, Germany

[4] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[5] Klinikum Chemnitz, Chemnitz, Germany

[6] Univ Heidelberg Hosp, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] Charite, Berlin, Germany

[9] Univ Hosp Cologne, Cologne, Germany

[10] Vrije Univ Brussel VUB, Lab Hematol & Immunol & Labor Myelomforsch, Jette, Belgium

[11] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[12] Coordinat Ctr Clin Trials KKS, Heidelberg, Germany

[13] Univ Tubingen Hosp, Tubingen, Germany

[14] Univ Med Ctr Mainz, Mainz, Germany

[15] Univ Hosp Bonn, Bonn, Germany

[16] Helios Hosp Berlin Buch, Buch, Germany

[17] Kath Krankenhaus Hagen, Hagen, Germany

[18] Univ Hamburg Hosp, Hamburg, Germany

[19] Univ Hosp Essen, Essen, Germany

来源：

LEUKEMIA | 2021年 / 35卷 / 10期

关键词：

PERIPHERAL NEUROPATHY; DEXAMETHASONE; LENALIDOMIDE;

D O I：

10.1038/s41375-021-01298-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3007 / 3011

页数：5

共 50 条

[21] Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma
Miguel, Jesus F. San
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin H.
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie-Lee
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul
BLOOD, 2008, 112 (11) : 242 - 242
[22] Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5
Mai, E. K.
Bertsch, U.
Duerig, J.
Kunz, C.
Haenel, M.
Blau, I. W.
Munder, M.
Jauch, A.
Schurich, B.
Hielscher, T.
Merz, M.
Huegle-Doerr, B.
Seckinger, A.
Hose, D.
Hillengass, J.
Raab, M. S.
Neben, K.
Lindemann, H-W
Zeis, M.
Gerecke, C.
Schmidt-Wolf, I. G. H.
Weisel, K.
Scheid, C.
Salwender, H.
Goldschmidt, H.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 150 - 151
[23] Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma.
Jagannath, Sundar
Durie, Brian G. M.
Wolf, Jeffrey Lee
Camacho, Elber S.
Irwin, David
Lutzky, Jose
McKinley, Marti
Gabayan, Afshin Eli
Mazumder, Amitabha
Crowley, John
Vescio, Robert
BLOOD, 2006, 108 (11) : 238A - 239A
[24] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Goldschmidt, Hartmut
Mai, Elias K.
Nievergall, Eva
Fenk, Roland
Bertsch, Uta
Tichy, Diana
Besemer, Britta
Duerig, Jan
Schroers, Roland
Metzler, Ivana V.
Haenel, Mathias
Mann, Christoph
Asemissen, Anne-Marie
Heilmeier, Bernhard
Huhn, Stefanie
Kriegsmann, Katharina
Weinhold, Niels
Luntz, Steffen P.
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Khandanpour, Cyrus
Knauf, Wolfgang
Munder, Markus
Geer, Thomas
Riesenberg, Hendrik
Thomalla, Joerg
Hoffmann, Martin
Raab, Marc-Steffen
Salwender, Hans
Weisel, Katja
BLOOD, 2021, 138
[25] Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and-MM5 trials
Mai, Elias K.
Baertsch, Marc-A.
Hielscher, Thomas
Bertsch, Uta
Schlenzka, Jana
Salwender, Hans J.
Munder, Markus
Fuhrmann, Stephan
Duehrsen, Ulrich
Brossart, Peter
Neben, Kai
Raab, Marc S.
Jauch, Anna
Seckinger, Anja
Hose, Dirk
Luntz, Steffen
Sonneveld, Pieter
Lokhorst, Henk
Martin, Hans
Lindemann, Hans-Walter
Blau, Igor Wolfgang
Scheid, Christof
Weisel, Katja
Haenel, Mathias
Duerig, Jan
Goldschmidt, Hartmut
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E43 - E43
[26] Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma (vol 46, pg 831, 2020)
Joseph, Nisha S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2702 - 2702
[27] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Sonneveld, Pieter
Schmidt-Wolf, Ingo G. H.
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor W.
Weisel, Katja C.
Wittebol, Shulamiet
Bos, Gerard M. J.
Stevens-Kroef, Marian
Scheid, Christof
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van der Velde, Helgi
Raymakers, Reinier
Schaafsma, Martijn R.
Kersten, Marie-Jose
van Marwijk-Kooy, Marinus
Duehrsen, Ulrich
Lindemann, Walter
Wijermans, Pierre W.
Lokhorst, Henk M.
Goldschmidt, Hartmut M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2946 - 2955
[28] LONG-TERM FOLLOW-UP OF ACT III: A PHASE II TRIAL OF RINDOPEPIMUT (CDX-110) IN NEWLY DIAGNOSED GLIOBLASTOMA
Lai, Rose K.
Recht, Lawrence D.
Reardon, David A.
Paleologos, Nina
Groves, Morris
Rosenfeld, Myrna R.
Davis, Thomas
Green, Jennifer
Heimberger, Amy
Sampson, John
NEURO-ONCOLOGY, 2011, 13 : 34 - 34
[29] Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
Mai, Elias K.
Nogai, Axel
Lokhorst, Henk M.
van der Holt, Bronno
Zweegman, Sonja
Weisel, Katja C.
Croockewit, Sandra
Jauch, Anna
Hillengass, Jens
Stevens-Kroef, Marian
Raab, Marc S.
Broijl, Annemiek
Bos, Gerard M. J.
Brossart, Peter
Ypma, Paula
Hanoun, Christine
Bertsch, Uta
Hielscher, Thomas
Salwender, Hans J.
Scheid, Christoph
Goldschmidt, Hartmut
Sonneveld, Pieter
HEMASPHERE, 2024, 8 (11):
[30] Bortezomib (BTZ) prior to and as maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM): Long-term follow-up of a phase II study
Goyal, S. D.
Uy, G.
DiPersio, J. F.
Vij, R.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →